Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
Provided By GlobeNewswire
Last update: Dec 1, 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC
– Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set
Read more at globenewswire.com
